The first Russian analogue of the antitumor drug Inlyta (axitinib) from Pfizer has appeared on the Russian pharmaceutical market. Axelpharma’s development, named after its active substance Axitinib, has been officially registered with the Ministry of Health of the Russian Federation.
The drug, intended for the treatment of renal cell cancer, is produced in the form of film-coated tablets in dosages of 1, 3, 5, 7 mg and is produced at the facilities of OncoTarget LLC, located in the Technopolis Moscow SEZ. It is clarified that the drug from Axelpharm is completely Russian – it has gone through all stages from the development and creation of a pharmaceutical substance to the release of the finished dosage form in Russia.
Axitinib is a treatment specifically designed for adults with advanced kidney cancer. It is recommended when the initial medication is no longer effective in stopping the progression of the disease. This makes it an excellent option for second-line therapy. It can be prescribed both as monotherapy and in combinations.
